CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/μL

HIV Medicine

Volumn 7, Issue 6, 2006, Pages 383-388

  Moore, David M ^a,b   Hogg, R S ^a,b   Yip, B ^a   Craib, K ^a   Wood, E ^a,b   Montaner, J S G ^a,b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiretroviral therapy; CD4; CD4 percentage; HIV infection; Prognosis

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HAZARD ASSESSMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; PATIENT COMPLIANCE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; KAPLAN-MEIERS ESTIMATE; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 33746430907     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00397.x     Document Type: Article

References (13)

1. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2004; 292: 251-265.
2. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Rockville, MD, US Department of Health and Human Services, 2004.
3. Hogg RS, Yip B, Chan KJ et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. J Am Med Assoc 2001; 286: 2568-2577.
4. Burcham J, Marmor M, Dubin N et al. CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 1991; 5: 365-372.
5. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in WIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989; 2: 114-124.
6. Wallace MR, Moss RB, Beecham HJ III et al. Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 358-362.
7. Centers for Disease Control and Prevention 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41: 1-19.
8. Le TP, Tribble DR, Zhou SY et al. Clinical significance of discordant CD4 count and CD4 percentage in HIV-infected individuals. AIDS 1997; 11: 1395-1396.
9. Gebo K, Gallant J, Keruly J, Moore R. Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immune Defic Syndr 2004; 36: 1028-1033.
10. British Columbia Centre for Excellence in HIV/AIDS. Therapeutic Guidelines for the Treatment of HIV/AIDS and Related Conditions. Vancouver, BC, Canada, British Columbia Centre for Excellence in HIV/ AIDS, 2001.
11. Hogg RS, Heath K, Bangsberg D et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16: 1051-1058.
12. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med 2003 139: 810-816.
13. Wood E, Hogg RS, Yip B et al. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J Infect Dis 2003; 188: 1421-1425.